The lens is indicated for use in patients undergoing cataract surgery who need treatment for near, intermediate, and distance vision needs with a single lens, the Switzerland-based company said.
“The AcrySof IQ PanOptix trifocal IOL is a significant innovation which further augments Alcon’s presbyopia correcting portfolio, leveraging Alcon’s market-leading AcrySof IQ IOL platform. It is designed to provide exceptional functional vision from near to intermediate, in addition to providing excellent distance vision,” Alcon surgical head of R&D Franck Leveiller said in prepared remarks.
“Today’s patients undergoing cataract surgery are more likely to seek vision correction options to address various lifestyle tasks such as reading books, using electronic tablets, working on computers and performing outdoor activities without the need for glasses or contact lenses. The AcrySof IQ PanOptix trifocal IOL is an important option that should provide these patients with a full range of vision and thus significantly reduced dependence on glasses,” Dr. Richard Packard of London’s Arnott Eye Associates said in a press release.
Last November, Alcon met with an FDA advisory panel to review the data behind its application for a new indication for its AcrySof IQ ReSTOR intraocular lens. The AcrySof IQ ReSTOR lens is already approved in the U.S. to treat presbyopia and cataracts.